News
Dermatologists often recommend nicotinamide — a form of Vitamin B3 — following skin cancer. A study of nearly 34,000 veterans ...
ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the broadening of its NAD+ precursor ...
Preclinical research suggests that NRH may be among the most potent and efficient of NAD+ precursors, and shows promise as a new therapeutic approach to ameliorating age-related NAD+ decline “There is ...
One of the most robust forms of intellectual property protection, a composition of matter patent grants ChromaDex (CDXC) exclusive rights to the disodium salt form of NMNH ChromaDex continuously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results